Literature DB >> 34247781

The Resilient Phenotype Induced by Prophylactic Ketamine Exposure During Adolescence Is Mediated by the Ventral Tegmental Area-Nucleus Accumbens Pathway.

Eric M Parise1, Lyonna F Parise1, Omar K Sial2, Astrid M Cardona-Acosta3, Trevonn M Gyles1, Barbara Juarez4, Dipesh Chaudhury5, Ming-Hu Han6, Eric J Nestler7, Carlos A Bolaños-Guzmán8.   

Abstract

BACKGROUND: Major depressive disorder is prevalent in children and adolescents and is associated with a high degree of morbidity throughout life, with potentially devastating personal consequences and public health impact. The efficacy of ketamine (KET) as an antidepressant has been demonstrated in adolescent rodents; however, the neurobiological mechanisms underlying these effects are unknown. Recent evidence showed that KET reverses stress-induced (i.e., depressive-like) deficits within major mesocorticolimbic regions, such as the prefrontal cortex, nucleus accumbens (NAc), and hippocampus, in adult rodents. However, little is known about KET's effect in the ventral tegmental area (VTA), which provides the majority of dopaminergic input to these brain regions.
METHODS: We characterized behavioral, biochemical, and electrophysiological effects produced by KET treatment in C57BL/6J male mice during adolescence (n = 7-10 per condition) within the VTA and its major projection regions, namely, the NAc and prefrontal cortex. Subsequently, molecular targets within the VTA-NAc projection were identified for viral gene transfer manipulations to recapitulate the effects of stress or KET treatment.
RESULTS: Repeated KET treatment produced a robust proresilient response to chronic social defeat stress. This effect was largely driven by Akt signaling activity within the VTA and NAc, and it could be blocked or recapitulated through direct Akt-viral-mediated manipulation. Additionally, we found that the KET-induced resilient phenotype is dependent on VTA-NAc, but not VTA-prefrontal cortex, pathway activity.
CONCLUSIONS: These findings indicate that KET exposure during adolescence produces a proresilient phenotype mediated by changes in Akt intracellular signaling and altered neuronal activity within the VTA-NAc pathway.
Copyright © 2021 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescence; Depression; Ketamine; Mesocorticolimbic; Prophylactic; Resilience

Mesh:

Substances:

Year:  2021        PMID: 34247781      PMCID: PMC8761260          DOI: 10.1016/j.biopsych.2021.05.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   12.810


  73 in total

1.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

Review 2.  A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.

Authors:  Susan Kim; Brittany S Rush; Timothy R Rice
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-05-08       Impact factor: 4.785

Review 3.  Ketamine as a novel antidepressant: from synapse to behavior.

Authors:  J W Murrough
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

Review 4.  The hippocampal-VTA loop: controlling the entry of information into long-term memory.

Authors:  John E Lisman; Anthony A Grace
Journal:  Neuron       Date:  2005-06-02       Impact factor: 17.173

5.  Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid.

Authors:  S Erhardt; G Engberg
Journal:  Acta Physiol Scand       Date:  2002-05

6.  Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.

Authors:  Demitri F Papolos; Martin H Teicher; Gianni L Faedda; Patricia Murphy; Steven Mattis
Journal:  J Affect Disord       Date:  2012-11-30       Impact factor: 4.839

7.  The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.

Authors:  J M Witkin; J A Monn; D D Schoepp; X Li; C Overshiner; S N Mitchell; G Carter; B Johnson; K Rasmussen; L M Rorick-Kehn
Journal:  J Pharmacol Exp Ther       Date:  2016-05-12       Impact factor: 4.030

Review 8.  Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable?

Authors:  Christopher J Kratochvil; Benedetto Vitiello; John Walkup; Graham Emslie; Bruce D Waslick; Elizabeth B Weller; William J Burke; John S March
Journal:  J Child Adolesc Psychopharmacol       Date:  2006 Feb-Apr       Impact factor: 2.576

9.  Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons.

Authors:  Dipesh Chaudhury; Jessica J Walsh; Allyson K Friedman; Barbara Juarez; Stacy M Ku; Ja Wook Koo; Deveroux Ferguson; Hsing-Chen Tsai; Lisa Pomeranz; Daniel J Christoffel; Alexander R Nectow; Mats Ekstrand; Ana Domingos; Michelle S Mazei-Robison; Ezekiell Mouzon; Mary Kay Lobo; Rachael L Neve; Jeffrey M Friedman; Scott J Russo; Karl Deisseroth; Eric J Nestler; Ming-Hu Han
Journal:  Nature       Date:  2012-12-12       Impact factor: 49.962

10.  Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.

Authors:  Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2020-02-24       Impact factor: 7.853

View more
  6 in total

1.  The BDNF-TrkB Pathway Acts Through Nucleus Accumbens D2 Expressing Neurons to Mediate Stress Susceptible Outcomes.

Authors:  Marco Pagliusi; Daniela Franco; Shannon Cole; Gessynger Morais-Silva; Ramesh Chandra; Megan E Fox; Sergio D Iñiguez; Cesar R Sartori; Mary Kay Lobo
Journal:  Front Psychiatry       Date:  2022-06-02       Impact factor: 5.435

Review 2.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

3.  Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective.

Authors:  Sandra Ledesma-Corvi; Elena Hernández-Hernández; M Julia García-Fuster
Journal:  Transl Psychiatry       Date:  2022-06-01       Impact factor: 7.989

4.  Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

5.  Acute (R,S)-Ketamine Administration Induces Sex-Specific Behavioral Effects in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle Kee; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Front Neurosci       Date:  2022-04-21       Impact factor: 4.677

6.  Predation Stress Causes Excessive Aggression in Female Mice with Partial Genetic Inactivation of Tryptophan Hydroxylase-2: Evidence for Altered Myelination-Related Processes.

Authors:  Evgeniy Svirin; Ekaterina Veniaminova; João Pedro Costa-Nunes; Anna Gorlova; Aleksei Umriukhin; Allan V Kalueff; Andrey Proshin; Daniel C Anthony; Andrey Nedorubov; Anna Chung Kwan Tse; Susanne Walitza; Lee Wei Lim; Klaus-Peter Lesch; Tatyana Strekalova
Journal:  Cells       Date:  2022-03-18       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.